Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate-to-severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 06 Aug 2021 Primary endpoint (Number of Participants With Investigators Global Assessment (IGA) Score of 0 or 1 and Reduction From Baseline of Greater Than or Equal to () 2 Points at Week 16) has been met, according to Results published in the British Journal of Dermatology.
- 06 Aug 2021 Results published in the British Journal of Dermatology
- 19 Jun 2020 According to a Sanofi media release, data from this trial will be shared with NMPA in the second half of 2020.